Solid Biosciences (SLDB)
Advancing gene therapy candidates for Duchenne and other rare neuromuscular and cardiac diseases.
Something off on this page? Send us feedback.
Develops investigational gene therapies led by SGT-003 for Duchenne, with additional programs for Friedreich's ataxia, CPVT, and genetic cardiomyopathies. The business has no approved products or product-sales revenue, so progress depends on clinical trials, regulatory approvals, manufacturing partners, and financing.
Advances a clinical-stage gene therapy pipeline for rare neuromuscular and cardiac diseases. Lead program SGT-003 targets Duchenne muscular dystrophy, while SGT-212, SGT-501, SGT-601, and earlier cardiac assets extend the platform into Friedreich's ataxia, CPVT, and genetic cardiomyopathies.
Built from a Duchenne patient-origin story, the company now operates from a single reportable segment and remains centered on research and development rather than product sales. Work is anchored in Massachusetts, while SGT-003 clinical execution reaches a late-stage multi-country trial.
Execution depends on trial enrollment and results, biologics approvals, manufacturing scale-up through third parties, and access to capital. Competition includes approved Duchenne therapies and investigational gene-therapy or rare-disease programs across its target conditions.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 16, 2026 | RBC Capital | Initiate | Rating: —Target: — | Target: $18 |
| Sep 14, 2026 | Loop Capital Markets | Target | Target: — | Target: $25 |
| Aug 27, 2026 | Cantor Fitzgerald | Reiterate | Rating: —Target: $16 | Target: $26 |
| Aug 21, 2026 | Truist Financial | Target | Target: — | Target: $20 |
| May 13, 2026 | Wedbush | Reiterate | Rating: —Target: — | Target: $16 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $377.7M · Total debt $20.2M · Total assets $420.6M · Shareholders' equity $374.1M
- Revenue
- $0
- Operating income
- −$57.4M
- Net income
- −$54.8M
No dividends on record.
| Institutions | ≈ 106.77% | 114.48M shares | |
|---|---|---|---|
| 163 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 8.99% | 9.64M shares | |
| 10 holders · as of Jul 7, 2026 | |||
| Adds to | 115.76% | ||
107.23M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (107.23M in the company's Sep 22, 2026 report, 98.45M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 115.76%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Ra Capital Management, L.P.Institution | 11.23% | 12.04M | as of Jun 30, 2026 |
Perceptive Advisors LLCInstitution | 11.10% | 11.91M | as of Jun 30, 2026 |
Bain Capital Life Sciences Investors, LLCInstitution | 9.15% | 9.81M | as of Jun 30, 2026 |
Invus Public Equities, L.P.Insider | 8.11% | 8.70M | filed May 5, 2026 |
BCLS II Investco, LPInstitution | 8.03% | 8.60M | filed Mar 10, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 18, 2026 | Kevin Tan | officer: CFO & Treasurer | −5,404 | $5.82 |
| Feb 18, 2026 | Gabriel Brooks | officer: Chief Medical Officer | 0 | |
| Feb 18, 2026 | David T. Howton | officer: Chief Operating Officer | −7,469 | $5.82 |
| Feb 18, 2026 | Paul Herzich | officer: Chief Technology Officer | −3,616 | $5.82 |
| Feb 18, 2026 | Ilan Ganot | director | −2,658 | $5.82 |
- Sarepta Therapeutics
Approved DMD gene therapy and exon-skipping portfolio
- REGENXBIO
Late-stage Duchenne microdystrophin gene therapy
- Capricor Therapeutics
Late-stage DMD cell therapy with FDA review
- Lexeo Therapeutics
FA cardiomyopathy gene therapy rival
- Edgewise Therapeutics
Muscle-preservation therapy across Duchenne and Becker
- Dyne Therapeutics
DMD exon 51 program with BLA submitted
- Novartis (ADR)
Owner of Avidity's late-stage neuromuscular RNA assets
- Biogen
Commercial FA therapy and pediatric expansion study
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Solid Biosciences | $8.91 | +4.33% | $840.8M | — | — | — | — |
| Sarepta Therapeutics | $20.93 | +3.92% | $2.13B | — | 36.4 | 1.1 | −34.3% |
| REGENXBIO | $8.15 | +3.48% | $407.4M | — | — | 2.3 | +405.7% |
| Capricor Therapeutics | $9.34 | +4.93% | $511.8M | — | — | — | — |
| Lexeo Therapeutics | $4.13 | +1.30% | $320.4M | — | — | — | — |
| Edgewise Therapeutics | $45.15 | +1.14% | $4.80B | — | — | — | — |
| Dyne Therapeutics | $17.45 | +1.93% | $3.20B | — | — | — | — |
| Novartis (ADR) | $141.21 | +0.16% | $267.96B | 21.3 | 15.0 | 4.8 | +0.9% |
| Biogen | $224.36 | +2.41% | $32.37B | 38.8 | 16.9 | 3.3 | +3.4% |
| Median | 30.0 | 16.9 | 2.8 | +2.2% |